Jianfeng Group: estimated net profit of 620 million yuan in the first half of the year, an increase of about 1201.86% over the same period last year

On July 14, Jianfeng Group issued a performance pre-increase announcement, predicting that the net profit attributable to shareholders of listed companies in the first half of 2025 will be about 620 million yuan, an increase of about 572.3759 million yuan compared with the same period last year, an increase of about 1201.86%. The significant increase in the net profit attributable to the shareholders of the listed company in the first half of

2025 was mainly due to the fact that Tasly Bio-Pharmaceutical Industry Group Co., Ltd. (Hereinafter referred to as "Tasly Group"), a joint venture of the Company accounted for by the equity method, sold its equity assets and obtained a large amount of non-recurring gains during the reporting period. The main reason for the loss of net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in the first half of

2025 is the loss of net profit attributable to the parent company of Tasly Group, a joint venture accounted for by equity method, after deducting the gains from equity transfer.